Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1

Although anti-retroviral therapies have greatly extended the lives of HIV infected individuals, current treatments are unable to completely eliminate virally infected cells. A number of latency reversing agents have been proposed for use in a "shock and kill" strategy to reactivate latent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2018-11, Vol.13 (11), p.e0208055
Hauptverfasser:	Cary, Daniele C, Peterlin, B Matija
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Anti-HIV Agents - pharmacology Anti-inflammatory agents Antioxidants Antioxidants (Nutrients) Antiretroviral agents Azepines - pharmacology Biology and Life Sciences CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - enzymology CD4-Positive T-Lymphocytes - virology Cell activation Cell culture Cell cycle Cell Line Cell surface Combination therapy Dosage and administration Dose-Response Relationship, Drug Drug resistance Drug Synergism Drug therapy Drug Therapy, Combination Enzyme Inhibitors - pharmacology Flavonoids Flavonoids - pharmacology Gene expression HIV HIV infections HIV Infections - drug therapy HIV Infections - enzymology HIV Infections - virology HIV patients HIV-1 - drug effects HIV-1 - physiology Human immunodeficiency virus Humans Immunology Inflammation Jurkat Cells Kinases Latency Low concentrations Lymphocytes Lymphocytes T MAP kinase Medicine Medicine and Health Sciences Polyphenols Primary Cell Culture Procyanidins Procyclidine Protein kinase C Proteins Research and Analysis Methods RNA polymerase Shock Surface markers T cells Therapeutics Transcription Triazoles - pharmacology Trimers Virus Latency - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!